Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5617329 | Journal of Vascular Surgery | 2017 | 7 Pages |
Abstract
The ACS NSQIP targeted vascular database shows that there has been increased adoption of pREVAR in recent years, with improved mortality and operative time over the 4-year study period. At this point, pREVAR has not yet been shown to be superior to cREVAR for rAAA, but these outcome improvements are encouraging and likely attributable to increased operator experience.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Samuel L. MD, Nii-Kabu MD, Matthew D. MD, Isabella J. MD, Roy M. MD,